Farnesyl transferase inhibitors: current developments and future perspectives

F A Eskens1, G Stoter, J Verweij

  • 1Department of Medical Oncology, Rotterdam Cancer Institute (Daniel den Hoed Kliniek), Rotterdam, The Netherlands. eskens@oncd.azr.nl

Cancer Treatment Reviews
|September 28, 2000
PubMed

Insights

Ras oncogene inhibition is a promising anticancer strategy. Farnesyl transferase inhibitors show potential, with early clinical studies defining new endpoints for treatment assessment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Ras oncogenes are critical drivers of human carcinogenesis.
  • Ras oncoprotein activity, regulated by farnesyl transferase, is essential for tumor development.
  • Targeting farnesyl transferase is a key strategy in anticancer drug development.

Purpose of the Study:

  • To review the role of Ras oncogenes in cancer.
  • To discuss the development and therapeutic potential of farnesyl transferase inhibitors.
  • To highlight the need for new endpoints in clinical trials for these agents.

Main Methods:

  • Review of preclinical and clinical data on farnesyl transferase inhibitors.
  • Analysis of the mechanism of Ras-dependent carcinogenesis.
  • Evaluation of emerging clinical trial designs and endpoints.

Main Results:

  • Farnesyl transferase inhibitors demonstrate significant in vitro and in vivo antitumor activity.
  • Early clinical studies with these inhibitors are underway.
  • New endpoints are required to accurately assess clinical value.

Conclusions:

  • Farnesyl transferase inhibitors represent a promising therapeutic avenue for Ras-driven cancers.
  • Further clinical investigation is necessary to establish their efficacy and optimal use.
  • Defining appropriate endpoints is crucial for successful clinical development.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...